The British Columbia PharmaCare (BC PharmaCare) is modernizing the Reference Drug Program (RDP). Effective immediately, transitional coverage is in place to allow affected patients to switch drugs, if needed, to retain full PharmaCare coverage. During transition, PharmaCare will cover all Modernized RDP fully covered drugs and all original RDP fully ... Read More
03
Jun2016
01
Jun2016
The Régie de l’assurance maladie du Québec (RAMQ) is scheduled to release its June update of the List of Medications on June 13, 2016 which will come into effect on June 15, 2016.
For more information and to see the list update schedule, please visit the RAMQ website.
26
May2016
Effective immediately, CADTH will be formally engaging with the pan-Canadian Pharmaceutical Alliance (pCPA) and will be including the pCPA office in the CADTH Common Drug Review (CDR) and pan-Canadian Oncology Drug Review (pCODR) processes. This will provide an opportunity for the pCPA office to receive relevant information on drugs reviewed ... Read More
25
May2016
Effective June 1, 2016, the Nova Scotia Pharmacare will begin funding INFLECTRA™ (infliximab) as an exception status benefit. For infliximab-naïve patients whose infliximab therapy is initiated after June 1, 2016, Inflectra will be the product approved for the following indications:
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriasis
Criteria Updates – Rheumatoid Arthritis
The Atlantic ... Read More
18
May2016
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of April 30, 2016:
23 negotiations are currently underway with 5 files added since the last update on March 31, 2016:
Arnuity Ellipta (fluticasone furoate): used for the treatment of asthma;
Breo Ellipta (fluticasone furoate/vilanterol): used for ... Read More
17
May2016
On May 5, 2016, the Canadian Agency for Drugs and Technologies in Health (CADTH) released a Recommendations Report on its project on Anti-Vascular Endothelial Growth Factor (VEGF) Drugs for Retinal Conditions.
CADTH has undertaken a therapeutic review comparing the clinical effectiveness and relative cost of three anti-VEGF drugs (aflibercept, bevacizumab, ranibizumab) ... Read More
03
May2016
The Patented Medicine Prices Review Board (PMPRB) has released its April 2016 NEWSletter. Some recent changes include:
Public Consultation on PMPRB Framework Modernization
In December 2015, the PMPRB released its 2015-2018 Strategic Plan, the culmination of a year-long strategic planning process that identified a new vision, a revised mission statement, and four ... Read More
22
Apr2016
To meet the needs of Quebec’s Ministry of Health and Social Services (MSSS), the Institut national d’excellence en santé et en services sociaux (INESSS) has developed a new drug review process for stable blood products for their addition to the Liste des produits du système du sang du Québec.
In addition, ... Read More
19
Apr2016
On April 1, 2016, the pan-Canadian Pharmaceutical Alliance (pCPA) issued the First Principles for Subsequent Entry Biologics (SEBs) to guide negotiations and inform expectations. These principles are now available on the pCPA website, found here.
The pCPA has also updated the status of negotiations on brand name drugs, included in ... Read More
11
Apr2016
On April 1, 2016, the pan-Canadian Pharmaceutical Alliance (pCPA) issued manufacturers a notification of first principles for subsequent entry biologics (SEBs) to guide negotiations and inform expectations. This information has not yet been posted on the pCPA website but is being shared with their permission.
Please see below for a copy ... Read More